Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT

Rang in Aktien #4062
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aktienkurs
$31.91
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$4.01B
Veränderung (1 Tag)
-2.77%
Veränderung (1 Jahr)
61.08%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)

Kategorie

Healthcare
Kursverlauf für Arcutis Biotherapeutics, Inc. (ARQT)
Höchster Schlusskurs: $27.20 am 2026-10-01

Niedrigster Schlusskurs: $21.80 am 2020-01-01
Kursverlauf der Aktie von Arcutis Biotherapeutics, Inc. von 2020 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -13.06%
2025 117.39%
2024 438.98%
2023 -84.13%
2022 -9.27%
2021 -38.74%
2020 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.18 23.62%
US
$251.29 835.90%
US
$137.07 -4.31%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH